Vanda Pharmaceuticals
VNDA
144 hedge funds and large institutions have $198M invested in Vanda Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 59 reducing their positions, and 32 closing their positions.
4.44% less ownership
Funds ownership: 88.12% → 83.69% (-4.4%)
7% less capital invested
Capital invested by funds: $214M → $198M (-$15.5M)
8% less funds holding
Funds holding: 157 → 144 (-13)
24% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 59
41% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 32
46% less call options, than puts
Call options by funds: $326K | Put options by funds: $609K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.02M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.73M |
| 3 |
Renaissance Technologies
New York
|
+$2.38M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.74M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.43M |
| 3 |
Millennium Management
New York
|
-$2.26M |
| 4 |
Morgan Stanley
New York
|
-$2.06M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$1.76M |
VNDA Hedge Fund Activity: Q1 2024 in Review
144 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2024, worth a combined $198M — down 7.2% from $214M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of VNDA and 19 opened new positions — a net loss of 13 holders — while 59 trimmed existing stakes and 45 added.
The largest buyer was Tang Capital Management, adding an estimated $6.02M. The largest seller was Pictet Asset Management, exiting entirely with an estimated $8.1M sold.
- 144 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2024, down from 157 in Q4 2023.
- Funds reported $198M of Vanda Pharmaceuticals stock for Q1 2024, down 7.2% quarter-over-quarter.
- 19 funds opened new Vanda Pharmaceuticals positions in Q1 2024 and 32 closed out, a net change of -13 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2024 was Tang Capital Management, an estimated $6.02M added.
- The largest Vanda Pharmaceuticals seller in Q1 2024 was Pictet Asset Management, an estimated $8.1M sold.
Based on aggregated 13F filings for Q1 2024.